Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 5/20 | 0.67 |
| ▸ | HTR2C | P28335 | 5/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | HTR3A | P46098 | 2/20 | 0.67 |
| ▸ | HTR5A | P47898 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL774763 | 1.00 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL774764 | 1.00 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5180106 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797293 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797289 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961312 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL3635467 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5652626 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961318 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4773941 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5390 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-12364682-B2 | Use of tegaserod in preparation of anti-tumor drug | QINGDAO HAIJI BIOMEDICINE CO., LTD. (CN) | 2025-07-22 | — | — | US | claimed |
| WO-2025122610-A1 | THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS | SEROTONIX LLC (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | claimed |
| CN-119789869-A | Pharmaceutical composition | 嘉惟思远制药有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | claimed |
| US-20240408071-A1 | NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER | NATIONAL CENTRE FOR CELL SCIENCE (IN) | 2024-12-12 | — | — | US | claimed |
| EP-1185263-A2 | RECEPTOR AGONISTS AND ANTAGONISTS | Respiratorius AB (SE) | 2002-03-13 | — | — | EP | claimed |
| EP-1173168-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | Respiratorius AB (SE) | 2002-01-23 | — | — | EP | claimed |
| WO-2001095902-A1 | A COMPOSITION COMPRISING A COMBINATION OF RECEPTOR AGONISTS AND ANTAGONISTS | RESPIRATORIUS AB (SE) | 2001-12-20 | — | — | WO | claimed |
| CN-1323200-A | 5HT4Novel oral formulations of agonists or antagonists | NOVARTIS AG (CH) | 2001-11-21 | — | — | CN | claimed |
| CN-1305806-A | Orally applied solid preparation of medicine difficult to dissolve | INST OF TOXIC MEDICINE PLA ACA (CN) | 2001-08-01 | — | — | CN | claimed |
| WO-2001041748-A2 | PHARMACEUTICAL COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL DISORDERS | NOVARTIS AG (CH) | 2001-06-14 | — | — | WO | claimed |
| EP-1104289-A2 | NEW ORAL FORMULATION FOR 5-HT4 AGONISTS OR ANTAGONISTS | Novartis AG (CH) | 2001-06-06 | — | — | EP | claimed |
| WO-2000076500-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-12-21 | — | — | WO | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| WO-2000010526-A2 | NEW ORAL FORMULATION FOR 5-HT4 AGONISTS OR ANTAGONISTS | NOVARTIS AG (CH) | 2000-03-02 | — | — | WO | claimed |